This is the first study to investigate the characteristics and treatment pattern of patients who have been clinically selected to receive anthracyclines and/or taxanes, focusing on Japanese patients with HER2− early-stage breast cancer who are at high risk of recurrence. This evidence concerns the gene ERBB2 and breast carcinoma.